hydroxycarbamide

Current Issues of Targeted Therapy of Polycythemia Vera

AUTOIMMUNE THROMBOCYTOPENIA , ,

AL Melikyan, IN Subortseva

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Anait Levonovna Melikyan, MD, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; e-mail: anoblood@ mail.ru

For citation: Melikyan AL, Subortseva IN. Current Issues of Targeted Therapy of Polycythemia Vera. Clinical oncohematology. 2021;14(3):355–60. (In Russ).

DOI: 10.21320/2500-2139-2021-14-3-355-360

ABSTRACT

The issues of therapy response criteria, first-line hydroxycarbamide intolerance and resistance to it as well as early changes in treatment strategy remain controversial and debatable in the management of polycythemia vera patients. The review outlines the results of literature data analysis related to the estimation of first-line therapy efficacy, it considers the spectrum and frequency of adverse events of hydroxycarbamide treatment, and focuses on the experience of using ruxolitinib, JAK2 inhibitor. The review provides results, including the long-term ones, of the comparative analysis of ruxolitinib use and the best available therapy of polycythemia vera patients with hydroxycarbamide resistance. The present review uses the materials of expert panel with the participation of Prof. Giuseppe A. Palumbo (University of Catania, Sicily, Italy) held on June 7, 2020.

Keywords: polycythemia vera, JAK2V617F, prognosis, hydroxycarbamide, ruxolitinib.

Received: December 22, 2020

Accepted: May 10, 2021

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014;59(4):31–56.
    [Melikyan AL, Turkina AG, Abdulkadyrov KM, et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Gematologiya i transfuziologiya. 2014;59(4):31–56. (In Russ)]
  2. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;62(1):25–60.
    [Melikyan AL, Turkina AG, Kovrigina AM, et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologiya i transfuziologiya. 2017;62(1):25–60. (In Russ)]
  3. Меликян А.Л., Ковригина А.М., Суборцева И.Н. и др. Национальные клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2018 г.) Гематология и трансфузиология. 2018;63(3):275–315. doi: 10.25837/HAT.2019.51.88.001.
    [Melikyan AL, Kovrigina AM, Subortseva IN, et al. National clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018). Gematologiya i transfuziologiya. 2018;63(3):275–315. doi: 10.25837/HAT.2019.51.88.001. (In Russ)]
  4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544.
  5. Танашян М.М., Кузнецова П.И., Лагода О.В. и др. Миелопролиферативные заболевания и ишемический инсульт. Анналы клинической и экспериментальной неврологии. 2014;8(2):41–5.
    [Tanashyan MM, Kuznetsova PI, Lagoda OV, et al. Myeloproliferative diseases and ischemic stroke. Annaly klinicheskoi i eksperimental’noi nevrologii. 2014;8(2):41–5. (In Russ)]
  6. Танашян М.М., Кузнецова П.И., Суборцева И.Н. и др. Хроническая и острая цереброваскулярная патология при Ph-негативных миелопролиферативных заболеваниях. Гематология и трансфузиология. 2016;61(3):146–50. doi: 18821/0234-5730-2016-61-3-146-150.
    [Tanashyan MM, Kuznetsova PI, Subortseva IN, et al. Chronic and acute cerebrovascular pathology in patients with Ph-negative myeloproliferative diseases. Gematologiya i transfuziologiya. 2016;61(3):146–50. doi: 10.18821/0234-5730-2016-61-3-146-150. (In Russ)]
  7. Меликян А.Л., Суборцева И.Н., Суханова Г.А. Тромбогеморрагические осложнения у больных Ph-негативными миелопролиферативными заболеваниями. Кровь. 2014;2(18):21–5.
    [Melikyan AL, Subortseva IN, Sukhanova GA. Thrombohemorrhagic complications in patients with Ph-negative myeloproliferative diseases. Krov’. 2014;2(18):21–5. (In Russ)]
  8. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И. и др. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412.
    [Subortseva IN, Kolosheinova TI, Pustovaya EI, et al. Polycythemia Vera: Literature Review and Own Data. Clinical oncohematology. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412. (In Russ)]
  9. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myel Leuk. 2015;15:27–33. doi: 10.1016/j.clml.2015.02.013.
  10. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81. doi: 10.1182/blood-2013-01-478891.
  11. Меликян А.Л., Суборцева И.Н., Шуваев В.А. и др. Современный взгляд на диагностику и лечение классических Ph-негативных миелопролиферативных заболеваний. Клиническая онкогематология. 2021;14(1):129–37. doi: 10.21320/2500-2139-2021-14-1-129-137.
    [Melikyan AL, Subortseva IN, Shuvaev VA, et al. Current View on Diagnosis and Treatment of Classical Ph-Negative Myeloproliferative Neoplasms. Clinical oncohematology. 2021;14(1):129–37. doi: 10.21320/2500-2139-2021-14-1-129-137. (In Russ)]
  12. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829–33. doi: 10.1182/blood-2008-09-176818.
  13. Palandri F, Elli ME, Benevolo G, et al. Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood. 2019;134(1):4174. doi: 10.1182/blood-2019-125388.
  14. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–3. doi: 10.1111/j.1365-2141.2009.08019.x.
  15. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, et al.; Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786–93. doi: 10.1111/bjh.13886.
  16. Kiladjian J-J, Pierre Z, Masayuki H, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):е226–е doi: 10.1016/S2352-3026(19)30207-8.
  17. Alvarez-Larran A, Verstovsek S, Perez-Encinas M, et al. Comparison of ruxolitinib and real-world best available therapy in terms of overall survival and thrombosis in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. EHA Library. 2018;215071:PF628.
  18. Curto-Garcia N, Baxter J, Harris E, et al. Molecular analysis in MAJIC PV correlation with clinical endpoints. HemaSphere. 2019;3(S1):740. doi: 10.1097/01.HS9.0000564676.68330.b5.

Dermatological Toxicity of Hydroxycarbamide

COMPLICATIONS OF ANTITUMOR TREATMENT ,

IN Subortseva, AL Melikyan, EA Gilyazitdinova, TI Kolosheinova, EI Pustovaya, EK Egorova, AM Kovrigina, AB Sudarikov, AO Abdullaev

National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Irina Nikolaevna Subortseva, MD, PhD, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; e-mail: soubortseva@yandex.ru.

For citation: Subortseva IN, Melikyan AL, Gilyazitdinova EA, et al. Dermatological Toxicity of Hydroxycarbamide. Clinical oncohematology. 2018;11(3):252–58.

DOI: 10.21320/2500-2139-2018-11-3-252-258

ABSTRACT

Hydroxycarbamide is an antitumor agent mainly used for treatment of Ph-negative myeloproliferative disorders and sickle cell disease. The development of skin ulcers is a rare but serious adverse event in long-term antitumor therapy. Hydroxycarbamide-induced ulcers are often multiple and bilateral, and usually occur in the lower legs, although they can occur in other regions of the body. The ulcers are small-sized and shallow with sharp margins and yellow fibrine-covered base. They cause constant severe, difficult to treat pain which is a characteristic sign. The drug withdrawal usually leads to spontaneous healing of ulcers. Regular dermatologic screening must be obligatory for all the patients receiving hydroxycarbamide. The present paper provides a literature review on dermatological toxicity of hydroxycarbamide and a clinical case description.

Keywords: hydroxycarbamide, adverse events, dermatologic screening, Ph-negative chronic myeloproliferative disorders.

Received: February 7, 2018

Accepted: May 4, 2018

Read in PDF 

REFERENCES

  1. Mathews CK. DNA synthesis as a therapeutic target: the first 65 years. FASEB J. 2012;26(6):2231–7. doi: 10.1096/fj.12-0602ufm.
  2. Yarbro JW, Leavell UW. Hydroxyurea: a new agent for the management of refractory psoriasis. J Ky Med Assoc. 1969;67:899–901.
  3. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994;266(5186):801–5. doi: 10.1126/science.7973634.
  4. Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11(3):403–14. doi: 10.1586/era.11.10.
  5. Adunyah SE, Chander R, Barner VK, Cooper RS. Regulation of c-jun mRNA expression by hydroxyurea in human K562 cells during erythroid differentiation. Biochim Biophys Acta. 1995;1263(2):123–32. doi: 10.1016/0167-4781(95)00079-v.
  6. Paleri V, Lindsey L. Oral ulcers caused by hydroxyurea. J Laryngol Otol. 2000;114(12):976–7. doi: 10.1258/0022215001904518.
  7. Lannemyr O, Kutti J. Hydroxyurea as a cause of drug fever in essential thrombocythaemia. Eur J Haematol. 1999;62(5):354–5. doi: 10.1111/j.1600-0609.1999.tb01917.x.
  8. Kalambokis G, Stefanou D, Arkoumani E, et al. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol. 2004;73(1):67–70. doi: 10.1111/j.1600-0609.2004.00252.x.
  9. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975;111(2):183–7. doi: 10.1001/archderm.1975.01630140041002.
  10. Bohn J, Hansen JP, Menne T. Ulcerative lichen planus-like dermatitis due to long-term hydroxyurea therapy. J Eur Acad Dermatol Venereol 1998;10(2):187–9. doi: 10.1111/j.1468-3083.1998.tb00726.x.
  11. Senet P, Aractingi S, Pornkuf M, et al. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol. 1995;133(3):455–9. doi: 10.1111/j.1365-2133.1995.tb02677.x.
  12. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol. 2001;26(2):141–8. doi: 10.1046/j.1365-2230.2001.00782.x.
  13. Bahadoran P, Castanet J, Lacour JP, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol. 1996;134(6):1161–2. doi: 10.1111/j.1365-2133.1996.tb07975.x.
  14. Marie I, Joly P, Levesque H, et al. Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol. 2000;18(4):536–7.
  15. Quattrone F, Dini V, Barbanera S, et al. Cutaneous ulcers associated with hydroxyurea therapy. J Tissue Viabil. 2013;22(4):112–21. doi: 10.1016/j.jtv.2013.08.002.
  16. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36(2):178–82. doi: 10.1016/s0190-9622(97)70276-7.
  17. Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol. 2002;47(1):146–7. doi: 10.1067/mjd.2002.120910.
  18. Ruzzon E, Randi ML, Tezza F, et al. Leg ulcers in elderly on hydroxyurea: a single center experience in Ph-myeloproliferative disorders and review of literature. Aging Clin Exp Res. 2006;18(3):187–90. doi: 10.1007/bf03324647.
  19. Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012;118(2):404–9. doi: 10.1002/cncr.26194.
  20. Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012;87(5):552–4. doi: 10.1002/ajh.23160.
  21. Salmon-Ehr V, Leborgne G, Vilque JP, et al. Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation. Rev Med Intern. 2000;21(1):30–4.
  22. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–3. doi: 10.1111/j.1365-2141.2009.08019.x.
  23. Kikuchi K, Arita K, Tateishi Y, et al. Recurrence of hydroxyurea-induced leg ulcer after discontinuation of treatment. Acta Derm Venereol. 2011;91(3):373–4. doi: 10.2340/00015555-1048.
  24. Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol. 2004;51(2):293–300. doi: 10.1016/j.jaad.2003.11.059.
  25. Young HS, Khan AS, Kendra JR, Coulson IH. The cutaneous side-effects of hydroxyurea. Clin Lab Haematol. 2000;22(4):229–32. doi: 10.1046/j.1365-2257.2000.00311.x.
  26. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48(3):439–41. doi: 10.1067/mjd.2003.74.
  27. Velez A, Garcia-Aranda J-M, Moreno J-C. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? J Eur Acad Dermatol Venereol. 1999;12(3):243–4. doi: 10.1111/j.1468-3083.1999.tb01037.x.
  28. Engstrom KG, Lofvenberg E. Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability. Blood. 1998;91(10):3986–91.
  29. Bader U, Banyai M, Boni R, et al. Leg ulcers in patients with myeloproliferative disorders: disease or treatment-related? Dermatology. 2000;200(1):45–8. doi: 10.1159/000018315.
  30. Hartmann K, Nagel S, Erichsen T, et al. Cutaneous ulcers following hydroxyurea therapy. Phlebologie. 2004;33(6):202–5.
  31. Kennedy BJ. Hydroxyurea-associated leg ulceration. Ann Intern Med. 1998;129(3):252. doi: 10.7326/0003-4819-129-3-199808010-00017.
  32. Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis. 1993;52(4):217–9.
  33. Stahl RL, Silber R. Vasculitic leg ulcers in chronic myelogenous leukemia. Am J Med. 1985;78(5):869–72. doi: 10.1016/0002-9343(85)90297-9.
  34. Burns DA, Sarkany I, Gaylarde P. Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Dermatol. 1980;5(4):447–9. doi: 10.1111/j.1365-2230.1980.tb01731.x.
  35. Stagno F, Guglielmo P, Consoli U, et al. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor. Blood. 1999;94(4):1479–80.
  36. Stone T, Berger A, Blumberg S, et al. A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma. Int Wound J. 2012;9(3):324–9.
  37. Natarajan S, Williamson D, Grey J, et al. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatol Treat. 2001;12(1):33–6. doi: 10.1080/095466301750163563.
  38. Tsuchiya S, Ichioka S, Sekiya N. Hydroxyurea-induced foot ulcer in a case of essential thrombocythaemia. J Wound Care. 2010;19(8):361–4. doi: 10.12968/jowc.2010.19.8.77715.
  39. Fioramonti P, Fino P, Parisi P, et al. A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase. In Vivo. 2012;26(6):1053–6.
  40. Martorell-Calatayud A, Requena С, Nagore-Enguidanos E, Guillen-Barona C. Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea. Actas Dermo-Sifiliograficas. 2009;100(9):804–7. doi: 10.1016/s1578-2190(09)70176-3.
  41. Varma S, Lanigan SW. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin Exp Dermatol. 1999;24(3):164–6. doi: 10.1046/j.1365-2230.1999.00443.x.
  42. Суборцева И.Н., Гилязитдинова Е.А., Колошейнова Т.И. и др. Предварительные результаты исследования по оценке эффективности и безопасности лечения пациентов с истинной полицитемией и эссенциальной тромбоцитемией цепэгинтерфероном α-2b. Клиническая онкогематология. 2017;10(4):581–2.[Subortseva IN, Gilyazitdinova EA, Kolosheinova TI, et al. Preliminary results of a study evaluating the efficacy and safety of cepeginterferon α-2b therapy of patients with polycythemia vera and essential thrombocythemia. Clinical oncohematology. 2017;10(4):581–2, abstract. (In Russ)]
  43. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014;59(4):31–56.[Melikyan AL, Turkina AG, Abdulkadyrov KM, et al. Clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative disorders (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Gematologiya i transfuziologiya. 2014;59(4):31–56. (In Russ)]
  44. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2017;62(1):25–60.[Melikyan AL, Turkina AG, Kovrigina AM, et al. Clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative disorders (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Gematologiya i transfuziologiya. 2017;62(1):25–60. (In Russ)]
  45. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных новообразований. Клиническая онкогематология. 2016;9(3):314–25. doi: 10.21320/2500-2139-2016-9-314-325.[Melikyan AL, Subortseva IN. Biology of Myeloproliferative Malignancies. Clinical oncohematology. 2016;9(3):314–25. doi: 10.21320/2500-2139-2016-9-314-325. (In Russ)]
  46. Franca ER, Teixeira MA, Matias Kde F, et al. Cutaneous effects after prolongaded use of hydroxyurea in polycythemia vera. Bras Dermatol. 2011;86(4):751–4.
  47. Poros A, Nadasdy K. Leg ulcer in hydroxyurea-treated patients. Haematologia. 2000;30:313–8. doi: 10.1163/156855900300109558.
  48. Yokota K, Tasaka T, Iwata K, et al. Huge postoperative ulcer following hydroxyurea therapy in a patient with polycythemia vera. Haematologica. 2003;88:ECR36.